Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Millan

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
European Journal of Pharmacology|May 23, 1998
WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortexM J Millan, M Brocco, S Veiga, et al.
British Journal of Pharmacology|November 11, 1999
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmissionC Sebban, X Q Zhang, B Tesolin-Decros, et al.
Brain Research|March 16, 1981
Stress-induced release of brain and pituitary beta-endorphin: major role of endorphins in generation of hyperthermia, not analgesiaM J Millan, R Przewłocki, M Jerlicz, et al.
Neuropharmacology|December 21, 2006
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonistsC Mannoury la Cour, S Vidal, V Pasteau, et al.
European Journal of Pharmacology|November 24, 1994
Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297J M Rivet, V Audinot, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1993
Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonistsM J Millan, J M Rivet, H Canton, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1994
5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigmM J Millan, J M Rivet, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626M J Millan, A Dekeyne, J M Rivet, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2002
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterizationM J Millan, A Newman-Tancredi, S Lochon, et al.
European Journal of Pharmacology|October 15, 1991
S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potencyM J Millan, H Canton, J M Rivet, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
European Journal of Pharmacology|May 23, 1998
WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortexM J Millan, M Brocco, S Veiga, et al.
British Journal of Pharmacology|November 11, 1999
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmissionC Sebban, X Q Zhang, B Tesolin-Decros, et al.
Brain Research|March 16, 1981
Stress-induced release of brain and pituitary beta-endorphin: major role of endorphins in generation of hyperthermia, not analgesiaM J Millan, R Przewłocki, M Jerlicz, et al.
Neuropharmacology|December 21, 2006
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonistsC Mannoury la Cour, S Vidal, V Pasteau, et al.
European Journal of Pharmacology|November 24, 1994
Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297J M Rivet, V Audinot, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1993
Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonistsM J Millan, J M Rivet, H Canton, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1994
5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigmM J Millan, J M Rivet, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626M J Millan, A Dekeyne, J M Rivet, et al.
Pharmacology, Biochemistry, and Behavior|March 13, 2002
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterizationM J Millan, A Newman-Tancredi, S Lochon, et al.
European Journal of Pharmacology|October 15, 1991
S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potencyM J Millan, H Canton, J M Rivet, et al.
Pageof 23